Navigation Links
New drug target improves memory in mouse model of Alzheimer's disease
Date:3/7/2012

Researchers at the University of California, San Diego, the Medical University of South Carolina, the University of Cincinnati, and American Life Science Pharmaceuticals of San Diego have validated the protease cathepsin B (CatB) as a target for improving memory deficits and reducing the pathology of Alzheimer's disease (AD) in an animal model representative of most AD patients. The study has been published in the online edition of the Journal of Alzheimer's Disease.

According to investigator Vivian Y. H. Hook, PhD, professor of the UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences and professor of neurosciences, pharmacology and medicine at the UCSD School of Medicine, the study is important because it could lead to new therapeutics that improve the memory deficits of AD.

Abnormal accumulation of brain amyloid-β peptides (Aβ) is thought to cause the memory loss and amyloid plaque pathology of AD. Aβ peptides are "cut" out from a larger protein called the amyloid precursor protein (APP) by an enzymatic "scissor" called β-secretase, and aggregate to form plaques in the brain regions responsible for memory. Inhibiting the β-secretase "scissors" from "cutting" the APP with a drug would reduce brain Aβ levels and thereby improve memory deficits and reduce amyloid plaque pathology. The vast majority of AD patients have wild-type (WT) β-secretase activity and thus the WT β-secretase has been a target of great interest for a long time.

Another protease, BACE1, has long been thought to be the -secretase involved in AD pathology, because deleting that gene from animal models reduces brain A and plaque pathology. However, deleting the BACE1 gene was reported to make memory deficits worse in a transgenic model having WT β-secretase activity.

Hook and colleagues set off to find a WT β-secretase target, which improves memory deficits while reducing amyloid plaque pathology. In the current paper, the researchers show that CatB is such a target because deleting that gene in a transgenic mouse model having WT -secretase activity improves memory deficits and reduces amyloid plaque, which develop in this model, mimicking that found in AD. In contrast, deleting the BACE1 gene in that transgenic model had no effect on memory deficits or pathology.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Marker of Ewing sarcoma: Potential new drug target?
2. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
3. New therapeutic target for most common solid cancer in childhood?
4. Fans Spread the Love on Target Facebook Page and Help Donate $1 Million to Five Charities
5. New Multivitamins Target Concern Over China's Quality Problems
6. Targeted delivery of losartan reduces liver inflammation and scarring
7. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
8. TV Ads Target House Members Who Voted for Obamacare
9. Targeting leukemia cells gene addiction presents new strategy for treatment
10. Hot Pepper Itch Remedy Targets Kidney Disease Patients Suffering From Chronic Pruritus
11. Americans for Responsible Health Care Launch Radio Ads Targeting Seven Democrats, Warning The People Are Watching...
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... ... connected home healthcare, will join forces with Healthwise ® at HIMSS ... Healthwise, the industry leader in evidence-based health education, technology and services, will demonstrate ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not traditional health ... according to the recent NEJM Catalyst Insights Report on the New Marketplace. ... Insights Council, a qualified group of U.S. executives, clinical leaders, and clinicians at ...
(Date:2/18/2017)... ... February 17, 2017 , ... CONTACT:, Glenn ... Beverly Hills plastic surgeon Dr. Glenn Vallecillos experiments SculpSure, the hot, ... "Traditionally, plastic surgery has been centered around that idea that to achieve ones ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume 2 features ... ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. Great for ... and choose from hand-crafted trend-setting designs with smooth animations that will add stylistic ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is a ... Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly credentialed ... roof. Smiles by Seese serves patients of all ages with excellence in general, restorative, ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017  Perrigo Company plc (NYSE, TASE: ... U.S. Food and Drug Administration for hydrocodone bitartrate and homatropine ... Hydrocodone bitartrate and homatropine methylbromide oral solution ... the symptomatic relief of cough in adults and children 6 ... months ending January 2017 were approximately $16 million.   ...
(Date:2/17/2017)... Feb. 17, 2017   FormFast , the leader ... new partnership with Engage , one of the ... . FormFast will serve as the forms automation ... with MEDITECH .  FormFast is ... to complement and enhance the electronic health record. FormFast,s ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017 Absorption ... biologics, and medical devices, is pleased to announce that ... has been selected as a winner of the 2017 ... SmartCEO Magazine and recognizes driven executives for their ... work ethic. The awards ceremony and celebration is on ...
Breaking Medicine Technology: